Protara Therapeutics Inc Stock Price, News & Analysis

Protara Therapeutics (TARA) announced significant updates regarding its clinical programs and financial results for the year ending December 31, 2022. Key highlights include expected data from the Phase 1a ADVANCED-1 trial for TARA-002 in treating non-muscle invasive bladder cancer (NMIBC) in 2Q23, and the initiation of Phase 2 trial activities for TARA-002 in lymphatic malformations (LMs) in 2H23. As of December 31, 2022, the company reported cash and equivalents of $102.3 million, anticipated to fund operations through 2025. However, TARA reported a net loss of $39 million for Q4, partly due to a $29.5 million goodwill impairment charge.

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company focused on innovative therapies for cancer and rare diseases, announced its participation in two upcoming investor conferences. These include the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 9:50 am ET in Boston, and the Oppenheimer 33rd Annual Healthcare Conference virtually on March 14, 2023, at 1:20 pm ET. Investors can access live webcasts of these events on the Company's website, with recordings available afterward. Protara's lead product, TARA-002, targets non-muscle invasive bladder cancer and lymphatic malformations.

Protara Therapeutics, Inc. (Nasdaq: TARA) announced participation in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on February 9, 2023, at 11:20 am ET in New York. The event aims to discuss the company’s efforts in developing transformative therapies for cancer and rare diseases. Protara’s lead program, TARA-002, is an investigational therapy for non-muscle invasive bladder cancer and lymphatic malformations. The webcast will be available on the Company’s website and archived for a limited period.

Protara Therapeutics (Nasdaq: TARA) has appointed Patrick Fabbio as Chief Financial Officer effective January 30, 2023. Fabbio brings over 30 years of experience from roles at Rafael Holdings and other pharmaceutical companies. CEO Jesse Shefferman expressed confidence in Fabbio's financial expertise to advance Protara's lead candidate, TARA-002, aimed at treating non-muscle invasive bladder cancer and lymphatic malformations. Fabbio received an inducement grant of options to purchase 300,000 shares at the closing price on his start date, set to vest over four years, enhancing stakeholder interest in the company's future prospects.

Protara Therapeutics (Nasdaq: TARA) announced the presentation of a Trials in Progress poster at the Annual Meeting of the Society of Urologic Oncology from November 30 to December 2, 2022. The poster highlights the ADVANCED-1 Phase 1 trial for the investigational therapy TARA-002, targeting non-muscle invasive bladder cancer (NMIBC). With a focus on an underserved patient population, the study aims to evaluate TARA-002's safety and preliminary anti-tumor activity. The trial is crucial for establishing a recommended dose for future clinical phases.